Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Private Advisor Group LLC

Private Advisor Group LLC raised its stake in Humacyte, Inc. (NASDAQ:HUMA) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 373,110 shares of the company’s stock after buying an additional 6,510 shares during the quarter. Private Advisor Group LLC owned about 0.31% of Humacyte worth $2,030,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the last quarter. Virtu Financial LLC acquired a new position in Humacyte in the first quarter valued at about $197,000. Vanguard Group Inc. lifted its position in Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after buying an additional 896,415 shares during the last quarter. Millennium Management LLC lifted its position in Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Humacyte by 62.7% during the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after purchasing an additional 97,931 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Stock Down 1.8 %

Shares of NASDAQ:HUMA opened at $5.32 on Wednesday. The firm’s 50 day moving average price is $5.66 and its 200 day moving average price is $6.05. The stock has a market cap of $633.53 million, a price-to-earnings ratio of -5.32 and a beta of 1.45. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $9.97. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). As a group, equities research analysts predict that Humacyte, Inc. will post -1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HUMA. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. TD Cowen reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $10.00.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares in the company, valued at $28,896,373.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the transaction, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 over the last three months. Insiders own 23.10% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.